---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-301520"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-07-13T12:39:54+00:00"
generated_at: "2026-07-13T12:45:10.996891+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "low"
source: SEC EDGAR
---

# Q32 Bio announces topline results from SIGNAL-AA Phase 2a Part B trial of bempikibart in alopecia areata

## Summary
- Topline results from 36-week Part B of SIGNAL-AA Phase 2a trial for bempikibart (ADX-914) in alopecia areata announced on July 13, 2026.
- Presentation filed as Exhibit 99.1 contains detailed efficacy, safety, and biomarker data; no numerical results provided in the 8-K body.
- Company cautions that additional data analyses may not support current beliefs; risks include trial costs, funding needs, and regulatory uncertainties.
- Forward-looking statements highlight potential differences between topline and final results; stock may react to data in the exhibit.

## SEC filing metadata
- accession: 0001193125-26-301520
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-07-13T12:39:54+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526301520/0001193125-26-301520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526301520/d143274d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-301520
- JSON: https://secwatch.observer/filing/0001193125-26-301520.json
- Plain text: https://secwatch.observer/filing/0001193125-26-301520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.